Olympus projects consolidated full-year revenue for 2026 to be 1.076 trillion yen, an increase of 7.3% YoY, with an operating profit of approximately 15.55 billion yen. Segment-wise, medical field revenue is expected to be 1.055 trillion yen, and digestive endoscopy business revenue approximately 744 billion yen. The recent organizational restructuring also details the performance of GIS and SIS segments.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7733","jir_company_name":"Olympus Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/7733-20260512-03.pdf","jir_short_summary":"Olympus projects consolidated full-year revenue for 2026 to be 1.076 trillion yen, an increase of 7.3% YoY, with an operating profit of approximately 15.55 billion yen. Segment-wise, medical field revenue is expected to be 1.055 trillion yen, and digestive endoscopy business revenue approximately 744 billion yen. The recent organizational restructuring also details the performance of GIS and SIS segments.","jir_summary":"### Performance Overview\nOlympus forecasts consolidated revenue for the full year of 2026 to be 1.076 trillion yen, representing a 7.3% increase from the previous year. Revenue from the medical field is expected to reach approximately 1.055 trillion yen, driven by business expansion following the organizational restructuring of the endoscopy and treatment device segments. Operating profit is expected to be around 15.55 billion yen, maintaining a steady growth trend. Segment-wise, detailed performance of GIS and SIS is provided, highlighting their significant roles in future growth strategies.\n\n### Outlook and Impact on Shareholders\nThrough restructuring of the endoscopy and treatment device businesses, Olympus plans to strengthen the performance of GIS and SIS segments and accelerate global expansion. While considering foreign exchange fluctuations, the company aims for stable growth in sales and profits. For shareholders, the focus is on dividends and stock stability, with expectations for long-term stock price appreciation driven by business expansion.","jir_financial_highlights":"Revenue: 1.076 trillion yen (\u21917.3% YoY)\nOperating Profit: about 15.55 billion yen (\u2191~10% YoY)\nConsolidated Revenue: 1.076 trillion yen (Forecast)","jir_category":"","jir_hashtags":"#Olympus, #IRResults, #JapaneseStocks","jir_key_figures":"Revenue: 1.076 trillion yen (forecast)\nOperating profit: about 15.55 billion yen (forecast)\nConsolidated revenue: 1.076 trillion yen (forecast)","jir_meta_title":"\u3010Olympus\u3011Full-Year Financial Results 2026 | Revenue of 1.076 Trillion Yen (\u21917.3%)","jir_meta_description":"An overview of Olympus' full-year financial results for 2026. Forecasted revenue of 1.076 trillion yen and operating profit of about 15.55 billion yen, with details on medical field expansion and business restructuring.","jir_og_title":"\u3010Olympus\u3011Full-Year Financial Results 2026 | Revenue of 1.076 Trillion Yen (\u21917.3%)","jir_og_description":"An explanation of Olympus' 2026 full-year financial summary and future outlook. Detailed projections for sales and profits, as well as key points of business restructuring.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6918,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-48263","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n